WAG
MNPR icon

Windsor Advisory Group’s Monopar Therapeutics MNPR Stock Holding History

Windsor Advisory Group’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,995
Closed -$55.8K – 65
2023
Q3 		$55.8K Buy
+17,995
New +$62.9K 0.13% 51

Other funds holding MNPR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GL
Gerber LLC Columbus, Ohio $179M AUM 24.35% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RRCM
Rappaport Reiches Capital Management Skokie`, Illinois $400M AUM 7.92% 1-Year Est. Return

Windsor Advisory Group's MNPR Position: Q4 2023 in Review

Windsor Advisory Group sold out of Monopar Therapeutics (MNPR) in Q4 2023, closing a stake of 17,995 shares — an estimated $55.8K sold.

Windsor Advisory Group first reported a position in MNPR in Q3 2023 and held it in 1 quarter. The position peaked at $55.8K in Q3 2023. 14 funds tracked by Wall St. Rank hold MNPR as of Q4 2023.

  • Windsor Advisory Group reported no remaining Monopar Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Windsor Advisory Group sold 17,995 Monopar Therapeutics shares in Q4 2023, an estimated $55.8K.
  • Windsor Advisory Group first reported a position in Monopar Therapeutics in Q3 2023 and held it in 1 quarter.
  • Windsor Advisory Group's Monopar Therapeutics position peaked at $55.8K in Q3 2023.
  • 14 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q4 2023.

Based on Windsor Advisory Group's 13F filing for Q4 2023, filed 22 Jan 2024.